<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Clinical Ophthalmology</journal-id><journal-title-group><journal-title>Clinical Ophthalmology (Auckland, N.Z.)</journal-title></journal-title-group><issn pub-type="ppub">1177-5467</issn><issn pub-type="epub">1177-5483</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22034553</article-id><article-id pub-id-type="pmc">3198407</article-id><article-id pub-id-type="doi">10.2147/OPTH.S24316</article-id><article-id pub-id-type="publisher-id">opth-5-1339</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>A prospective, randomized, fellow eye comparison of WaveLight<sup>&#x000ae;</sup> Allegretto Wave<sup>&#x000ae;</sup> Eye-Q versus VISX CustomVue&#x02122; STAR S4 IR&#x02122; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moshirfar</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="af1-opth-5-1339">1</xref><xref ref-type="corresp" rid="c1-opth-5-1339"/></contrib><contrib contrib-type="author"><name><surname>Betts</surname><given-names>Brent S</given-names></name><xref ref-type="aff" rid="af2-opth-5-1339">2</xref></contrib><contrib contrib-type="author"><name><surname>Churgin</surname><given-names>Daniel S</given-names></name><xref ref-type="aff" rid="af3-opth-5-1339">3</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Maylon</given-names></name><xref ref-type="aff" rid="af1-opth-5-1339">1</xref></contrib><contrib contrib-type="author"><name><surname>Neuffer</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="af1-opth-5-1339">1</xref></contrib><contrib contrib-type="author"><name><surname>Sikder</surname><given-names>Shameema</given-names></name><xref ref-type="aff" rid="af4-opth-5-1339">4</xref></contrib><contrib contrib-type="author"><name><surname>Church</surname><given-names>Dane</given-names></name><xref ref-type="aff" rid="af5-opth-5-1339">5</xref></contrib><contrib contrib-type="author"><name><surname>Mifflin</surname><given-names>Mark D</given-names></name><xref ref-type="aff" rid="af1-opth-5-1339">1</xref></contrib></contrib-group><aff id="af1-opth-5-1339"><label>1</label>John A Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, UT, USA</aff><aff id="af2-opth-5-1339"><label>2</label>Temple University School of Medicine, Philadelphia, PA, USA</aff><aff id="af3-opth-5-1339"><label>3</label>University of Arizona College of Medicine &#x02013; Phoenix, Phoenix, AZ, USA</aff><aff id="af4-opth-5-1339"><label>4</label>Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA</aff><aff id="af5-opth-5-1339"><label>5</label>Virginia Commonwealth University School of Medicine, Richmond, VA, USA</aff><author-notes><corresp id="c1-opth-5-1339">Correspondence: Majid Moshirfar, John A Moran Eye Center, 65 Mario Capecchi Drive, Salt Lake City, UT 84132, USA, Tel +1 801 587 3020, Fax +1 801 947 9286, Email <email>majid.moshirfar@hsc.utah.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2011</year></pub-date><volume>5</volume><fpage>1339</fpage><lpage>1347</lpage><permissions><copyright-statement>&#x000a9; 2011 Moshirfar et al, publisher and licensee Dove Medical Press Ltd</copyright-statement><copyright-year>2011</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To compare outcomes in visual acuity, refractive error, higher-order aberrations (HOAs), contrast sensitivity, and dry eye in patients undergoing laser in situ keratomileusis (LASIK) using wavefront (WF) guided VISX CustomVue and WF optimized WaveLight Allegretto platforms.</p></sec><sec><title>Methods</title><p>In this randomized, prospective, single-masked, fellow eye study, LASIK was performed on 44 eyes (22 patients), with one eye randomized to WaveLight Allegretto, and the fellow eye receiving VISX CustomVue. Postoperative outcome measures at 3 months included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refractive error, root-mean-square (RMS) value of total and grouped HOAs, contrast sensitivity, and Schirmers testing.</p></sec><sec><title>Results</title><p>Mean values for UDVA (logMAR) were &#x02212;0.067 &#x000b1; 0.087 and &#x02212;0.073 &#x000b1; 0.092 in the WF optimized and WF guided groups, respectively (<italic>P</italic> = 0.909). UDVA of 20/20 or better was achieved in 91% of eyes undergoing LASIK with both lasers while UDVA of 20/15 or better was achieved in 64% of eyes using the Allegretto platform, and 59% of eyes using VISX CustomVue (<italic>P</italic> = 1.000). In the WF optimized group, total HOA increased 4% (<italic>P</italic> = 0.012), coma increased 11% (<italic>P</italic> = 0.065), and spherical aberration increased 19% (<italic>P</italic> = 0.214), while trefoil decreased 5% (<italic>P</italic> = 0.490). In the WF guided group, total HOA RMS decreased 9% (<italic>P</italic> = 0.126), coma decreased 18% (<italic>P</italic> = 0.144), spherical aberration decreased 27% (<italic>P</italic> = 0.713) and trefoil decreased 19% (<italic>P</italic> = 0.660). One patient lost one line of CDVA secondary to residual irregular astigmatism.</p></sec><sec><title>Conclusion</title><p>Both the WaveLight Allegretto and the VISX CustomVue platforms had equal visual and safety outcomes. Most wavefront optimized HOA values trended upward, with a statistically significant increase in total HOA RMS. Eyes treated with the WF guided platform showed a decreasing trend in HOA values.</p></sec></abstract><kwd-group><kwd>wavefront guided</kwd><kwd>wavefront optimized</kwd><kwd>laser in situ keratomileusis</kwd><kwd>LASIK</kwd><kwd>Allegretto</kwd><kwd>VISX</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Conventional laser refractive surgery platforms are capable of correcting lower-order aberrations, such as hyperopia, myopia, and astigmatism. Higher-order aberrations (HOAs), such as coma, spherical aberration, and trefoil, are induced by, and remain uncorrected in, traditional laser in situ keratomileusis (LASIK) surgery.<xref ref-type="bibr" rid="b1-opth-5-1339">1</xref>,<xref ref-type="bibr" rid="b2-opth-5-1339">2</xref></p><p>Although conventional LASIK surgery is mostly accurate, abundant research has shown reoperation rates for primary myopic keratorefractive surgery are between 5.5% and 19.2%.<xref ref-type="bibr" rid="b3-opth-5-1339">3</xref>&#x02013;<xref ref-type="bibr" rid="b9-opth-5-1339">9</xref> When HOAs cannot be corrected, image quality may suffer.<xref ref-type="bibr" rid="b1-opth-5-1339">1</xref>,<xref ref-type="bibr" rid="b2-opth-5-1339">2</xref>,<xref ref-type="bibr" rid="b10-opth-5-1339">10</xref>&#x02013;<xref ref-type="bibr" rid="b13-opth-5-1339">13</xref> The HOAs call for more advanced optical measurements and more sophisticated laser algorithms. These laser algorithms are found in wavefront (WF) based treatments, which have been shown to diminish induced HOAs compared to traditional LASIK, and increase predictability of visual outcomes.<xref ref-type="bibr" rid="b14-opth-5-1339">14</xref>&#x02013;<xref ref-type="bibr" rid="b18-opth-5-1339">18</xref> As WF based methods have evolved rapidly over the years, an important question is whether there are significant differences in the induced HOAs and visual outcomes between specific WF guided and WF optimized platforms used in LASIK.</p><p>To date, multiple studies have compared WF guided and WF optimized platforms in LASIK surgery.<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref>&#x02013;<xref ref-type="bibr" rid="b24-opth-5-1339">24</xref> The data shows varied results, with some studies suggesting an advantage to WF guided platforms,<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref>,<xref ref-type="bibr" rid="b22-opth-5-1339">22</xref>&#x02013;<xref ref-type="bibr" rid="b24-opth-5-1339">24</xref> and others showing no significant difference between the two platforms.<xref ref-type="bibr" rid="b20-opth-5-1339">20</xref>,<xref ref-type="bibr" rid="b21-opth-5-1339">21</xref> In this prospective, randomized, fellow eye study, we compared WF guided VISX CustomVue platform (Abbott Medical Optics [AMO], Santa Ana, CA) with WF optimized WaveLight Allegretto platform (Alcon, Inc, H&#x000fc;enberg, Switzerland) in the same patient undergoing LASIK, with respect to visual acuity, refractive error, HOAs, contrast sensitivity, and dry eyes.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>This prospective, single masked, randomized, fellow eye study evaluated and compared the outcomes of LASIK performed on 44 eyes (22 patients) using the VISX CustomVue laser system and the WaveLight Allegretto laser system. Patients were recruited and enrolled at the John A Moran Eye Center, Department of Ophthalmology and Visual Science, University of Utah, between December 2010 and July 2011. All patients were over the age of 21.</p><p>The University of Utah Hospital Institutional Review Board approved the research protocol in accordance with the tenets of the Declaration of Helsinki. All patients provided informed consent after they received an explanation of the procedure, including all risks and benefits. All patients had a preoperative discussion of relevant medical history, including history of herpetic eye disease and family history of keratoconus.</p><p>Patients were excluded if they had a history of clinically significant lens opacity, previous corneal or intraocular surgery, thin corneas, keratoconus, unstable refraction, amblyopia, or autoimmune disease; were pregnant or breastfeeding; or were on immunosuppressive therapy. Patients desiring monovision were not included in the study.</p><p>Eligible patients were scheduled for bilateral LASIK and correction for distance in both eyes. The patients were randomly assigned (Research Randomizer software &#x02013; Urbaniak, <ext-link ext-link-type="uri" xlink:href="www.randomizer.org">www.randomizer.org</ext-link>) to treatment in one eye with the WaveLight Allegretto system (WF optimized group), which utilizes the WaveLight<sup>&#x000ae;</sup> Allegretto 400 Hz Wave<sup>&#x000ae;</sup> Eye-Q Laser. The fellow eye was assigned treatment with the VISX CustomVue&#x02122; STAR S4 IR&#x02122; Excimer Laser with Active-Track&#x02122; iris registration (WF guided group). The patients were blinded as to which laser was used for treatment in each eye. No patient had LASIK enhancement at any time during the study.</p><p>Soft contact lenses were discontinued 2 weeks before screening and rigid gas permeable contact lenses were discontinued 6 weeks before screening. All patients had a preoperative examination including manifest refraction (MRX) and cycloplegic refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), tonometry, slitlamp examination, and dilated fundus evaluation. Corneal topography and thickness were measured using the Pentacam (OCULUS Optikger&#x000e4;te GmbH, Wetzlar, Germany) and Humphrey Atlas (Carl Zeiss Meditec, Inc, Jena, Germany) systems. Pupil size was measured in the dark using the Colvard pupillometer (Oasis Medical, Inc, Glendora, CA). Contrast sensitivity was performed using the VectorVision CSV-1000 (Dayton, OH) chart in controlled mesopic (70 lux) conditions at three, six, twelve, and 18 cycles per degree. Schirmers testing evaluation for dry eye was measured in millimeters with topical anesthetic after 5 minutes. MRX and WF measurements were repeated on two separate visits to ensure refractive stability.</p><p>All eyes received five preoperative wavefront analyses using the VISX CustomVue WaveScan aberrometer v 3.62 (Fourier) (AMO), without pharmacologic intervention, under mesopic conditions, with a minimum pupil diameter of 6.0 mm. The emmetropic correction target was based on MRX, topography, and wavefront analysis for the WF guided group. For the WF optimized group, emmetropic correction target was based on topography and MRX. Iris registration was obtained for eyes receiving WF guided treatment. Previously established Moran Laser Center WF guided LASIK nomograms were followed for both the Allegretto and the CustomVue treatments. The nomograms were generated with Datagraph-med refractive outcomes software (v 3.20a; Ingenieurb&#x000fc;ro Pieger GmbH, Wendelstein, Germany) using a minimum of 50 eyes for each wavefront platform with a minimum follow-up of 3 months.</p><p>All LASIK flaps were created with an iFS&#x02122; Advanced Femtosecond Laser (AMO) at 150 kHz in a raster pattern with bed energy of 1.15 &#x003bc;J, side cut energy of 2.00 &#x003bc;J, and pocket enabled. Flaps were created with an intended thickness of 110 &#x003bc;m, diameter of 8.4 to 9.0 mm, superior hinge angle of 55&#x000b0;, and a side cut angle of 70&#x000b0;. If the 8.0 mm maximum intended ablation diameter exceeded the flap diameter, the hinge and flap were shielded during ablation. All surgeries were performed by Majid Moshirfar and Mark D Mifflin.</p><p>Postoperatively, each eye received one drop of gatifloxacin 0.3% (Allergan Inc, Irvine, CA) and prednisolone acetate 1% (Allergan, Inc). The prednisolone acetate was continued hourly on postoperative day 1, and then four times daily for 6 additional days. The gatifloxacin was continued four times daily for 1 week.</p><p>Patients were seen and data was collected at 1 day, 1 week, and 1 and 3 months after surgery. UDVA and CDVA were tested using a standard Snellen eye chart. Visual acuity was recorded in both Snellen notation and logarithm of the minimum angle of resolution (logMAR) format. Evaluation of contrast sensitivity, dry eye, and HOAs were performed. HOAs including total HOA root mean square (RMS), coma Z(3,1), trefoil Z(3,3), and spherical aberration Z(4,0), were measured using the WaveScan aberrometer. Undilated scans of both eyes were taken at 3 months postoperatively regardless of the wavefront platform used for treatment. Subjective outcomes were recorded using the Quality of Life Impact of Refractive Correction (QIRC) instrument. The ratings from the QIRC were interpreted using the guidelines set by Pesudovs et al.<xref ref-type="bibr" rid="b25-opth-5-1339">25</xref></p></sec><sec><title>Statistics</title><p>After the study was completed, the results were compiled and the data unmasked for statistical analysis. MRX, refractive error, visual acuity, contrast sensitivity, HOA values for coma, trefoil, and sphere, and HOA RMS wavefront aberration values were treated as continuous variables and analyzed for significance by using a paired Student&#x02019;s <italic>t</italic>-test. A <italic>P</italic> value of 0.05 or less was considered statistically significant. Data analysis was performed using Microsoft Excel (Microsoft Corp, Redmond, WA).</p></sec><sec><title>Results</title><p>22 patients (44 eyes) with 3 months of postoperative care were evaluated in this study. The sample population consisted of 15 women and seven men with a mean age of 31.2 years &#x000b1; 6.3 standard deviation (SD) (range 23 to 53 years). Baseline data showed no significant differences in preoperative CDVA or refractive error (<xref ref-type="table" rid="t1-opth-5-1339">Table 1</xref>).</p><sec><title>Visual acuity</title><p>UDVA and CDVA were not statistically different between the groups at 1 or 3 months (<xref ref-type="table" rid="t2-opth-5-1339">Table 2</xref>). Postoperatively, 20/15 UDVA was achieved in 64% and 59% of the eyes in the WF optimized and WF guided groups, respectively. Three months after surgery, 91% of the eyes in both groups achieved 20/20 UDVA (<xref ref-type="table" rid="t3-opth-5-1339">Table 3</xref>). Postoperatively, spherical equivalent and sphere measurements decreased significantly in the WF optimized group compared to the WF guided group at 1 and 3 months (<italic>P</italic> = 0.020, <italic>P</italic> = 0.017). There was no significant difference in cylinder measurements in either group before or after surgery.</p></sec><sec><title>Safety, efficacy, and predictability</title><p>At 1 month, 21 eyes (95%) in the WF optimized group and 18 (81%) in the WF guided group were within &#x000b1; 0.50 diopters (D) of emmetropia. In addition, ten eyes (45%) in the WF optimized group and six eyes (27%) in the WF guided group were within &#x000b1;0.25 D of emmetropia (<italic>P</italic> = 0.035). Although there was a significant difference in emmetropia at 1 month, this did not remain significant at 3 months (<xref ref-type="table" rid="t3-opth-5-1339">Table 3</xref>).</p><p>At 3 months, one eye (5%) in the WF optimized group lost one line of CDVA. The vision loss was attributed to residual irregular astigmatism confirmed by topography. No other eyes in the study population lost any lines of CDVA. Nine eyes (41%) in the WF optimized group maintained equal CDVA compared to twelve eyes (55%) in the WF guided group. Eleven eyes (50%) in the WF optimized group and nine eyes (41%) in the WF guided group gained one line of CDVA. One eye in both groups gained two lines (<italic>P</italic> = 1.000).</p></sec><sec><title>Schirmers testing</title><p>The preoperative average Schirmers test value for the WF optimized group was 19.9 mm &#x000b1; 9.95 and 22.1 mm &#x000b1; 9.98 for the WF guided group. At 1 month the values were 20.3 mm &#x000b1; 8.52 and 21.1 mm &#x000b1; 10.2 for the WF optimized group and the WF guided group, respectively. The 3 months postoperative values were 21.1 mm &#x000b1; 7.83 for the WF optimized group and 20 mm &#x000b1; 8.12 for the WF guided group. There was no significant difference in Schirmers testing between both groups during the study period (<italic>P</italic> &#x02265; 0.081).</p></sec><sec><title>Contrast sensitivity</title><p>Contrast sensitivity did not change significantly in either group when preoperative measurements were compared to postoperative measurements (<italic>P</italic> &#x02265; 0.07) (<xref ref-type="fig" rid="f1-opth-5-1339">Figure 1</xref>).</p></sec><sec><title>Higher-order aberrations</title><p>At 3 months postoperatively, 15 eyes (68%) in each group completed CustomVue WaveScan analysis. The only statistically significant change discovered was a 4% increase in total HOA RMS (<italic>P</italic> = 0.012) in the WF optimized group. In this group, other HOAs had nonsignificant changes, which showed the following: coma increased 11% (<italic>P</italic> = 0.065), trefoil decreased 5% (<italic>P</italic> = 0.239) and spherical aberration increased 19% (<italic>P</italic> = 0.214) (<xref ref-type="fig" rid="f2-opth-5-1339">Figure 2</xref>). The WF guided group showed a decreasing trend in HOA values, with total HOA RMS, coma, trefoil, and spherical aberration decreasing 9% (<italic>P</italic> = 0.126), 18% (<italic>P</italic> = 0.144), 19% (<italic>P</italic> = 0.660), and 28% (<italic>P</italic> = 0.713) respectively (<xref ref-type="fig" rid="f3-opth-5-1339">Figure 3</xref>). There were no significant differences in preoperative or postoperative HOA values between the WF guided or WF optimized groups.</p></sec><sec><title>Quality of life</title><p>Mean QIRC values were obtained preoperatively and at 3 months postoperatively. Postoperative mean QIRC values at 3 months were 27% higher than preoperative values (<italic>P</italic> &#x0003c; 0.001) (<xref ref-type="fig" rid="f4-opth-5-1339">Figure 4</xref>).</p></sec><sec><title>Complications</title><p>No intraoperative complications occurred in the study population. One eye lost one line of CDVA in the WF optimized group. The patient had 4.00 D of astigmatism preoperatively, and the loss of vision was determined to be due to residual astigmatism with some irregularity confirmed by topography. No other eyes in the sample population lost any lines of CDVA. Complications included three eyes with nonvisually significant microstriae, one of which was slightly overcorrected. All patients with microstriae were in the &#x02212;7.00 D range preoperatively. The overcorrected eye was in the WF guided group, and had a terminal spherical equivalent measuring +1.75 D. This patient remains at 20/20 UDVA. No other complications were observed.</p></sec></sec><sec><title>Discussion</title><p>In a recent retrospective study comparing VISX Custom-Vue to WaveLight Allegretto platforms in LASIK surgery, Perez- Straziota et al found there were no significant differences in visual outcomes or induced HOAs.<xref ref-type="bibr" rid="b20-opth-5-1339">20</xref> To the best of our knowledge, we report the first prospective, randomized, single masked, fellow eye study between these lasers.</p><p>Our study supports previous comparative research that the VISX CustomVue WF guided platform and the WaveLight Allegretto WF optimized platform are effective and predictable in LASIK surgery.<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref>&#x02013;<xref ref-type="bibr" rid="b23-opth-5-1339">23</xref>,<xref ref-type="bibr" rid="b26-opth-5-1339">26</xref> We found a statistically significant difference in postoperative sphere and spherical equivalent in the WF optimized group. Additionally, a greater percentage of the WF optimized eyes fell within &#x000b1;0.50 D of emmetropia at 1 month, but at 3 months both groups were equal. Cylinder values did not differ significantly between the wavefront platforms. There were no statistically significant differences in outcomes of UDVA, CDVA, contrast sensitivity, or Schirmers testing at 3 months postoperatively.</p><p>Comparisons of various WF guided and WF optimized platforms in LASIK have not shown a consistent advantage in reduction of HOAs in either platform.<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref>,<xref ref-type="bibr" rid="b21-opth-5-1339">21</xref>&#x02013;<xref ref-type="bibr" rid="b24-opth-5-1339">24</xref> In comparing two WF guided platforms, Alcon CustomCornea and VISX CustomVue, Moshirfar et al observed that both platforms led to a small increase in total HOAs.<xref ref-type="bibr" rid="b26-opth-5-1339">26</xref> Several authors have compared similar Allegretto WF guided and Allegretto WF optimized lasers prospectively.<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref>,<xref ref-type="bibr" rid="b21-opth-5-1339">21</xref>,<xref ref-type="bibr" rid="b23-opth-5-1339">23</xref> Padmanabhan et al concluded there was no significant difference between the two modalities in terms of visual acuity or refractive outcomes, although WF guided technology induced significantly fewer HOAs.<xref ref-type="bibr" rid="b19-opth-5-1339">19</xref> Miraftab et al saw no significant difference of induced HOAs between either group.<xref ref-type="bibr" rid="b21-opth-5-1339">21</xref> Lastly, Stonecipher and Kezirian observed that WF guided treatment was more beneficial for patients with a high degree of preoperative HOA RMS.<xref ref-type="bibr" rid="b23-opth-5-1339">23</xref> Brint,<xref ref-type="bibr" rid="b22-opth-5-1339">22</xref> followed by Tran and Shah,<xref ref-type="bibr" rid="b24-opth-5-1339">24</xref> compared Alcon CustomCornea WF guided treatment to Allegretto WF optimized treatment. Both found a statistically significant increase in HOAs using the Allegretto platform in comparison to WF guided platform.<xref ref-type="bibr" rid="b22-opth-5-1339">22</xref>,<xref ref-type="bibr" rid="b24-opth-5-1339">24</xref></p><p>We observed a similar pattern of results for HOAs after LASIK. We found a significant increase in mean total HOA RMS in the WF optimized group, along with a nonsignificant trend of decrease in trefoil, and increase in coma and spherical aberration. Conversely, the WF guided group showed a nonsignificant decreasing trend in HOA values postoperatively. Similarly, Miraftab et al found postoperative nonstatistically significant increasing trends in total HOA, C7 vertical coma, and spherical aberration, with a decreasing trend in trefoil for their WF optimized platform.<xref ref-type="bibr" rid="b21-opth-5-1339">21</xref> Also, Randleman et al showed a nonsignificant trend of increases in total HOA, coma, trefoil, and spherical aberration in their WF optimized LASIK study.<xref ref-type="bibr" rid="b18-opth-5-1339">18</xref></p><p>In regards to patient satisfaction with WF guided vs WF optimized LASIK, Yu et al showed no significant difference in objective measurements on the QIRC questionnaire.<xref ref-type="bibr" rid="b27-opth-5-1339">27</xref> We observed significant increases postoperatively in quality of life measures in our study population. We were unable to compare VISX CustomVue to WaveLight Allegretto using the QIRC because this survey instrument does not separate subjective results based on each eye. We administered an additional subjective survey, but the data received was limited and no conclusions could be drawn. While short subjective surveys after LASIK have allowed for conclusions in previous literature,<xref ref-type="bibr" rid="b28-opth-5-1339">28</xref> we believe our ten item survey instrument would benefit from a larger sample size.</p><p>Our study showed one eye that lost one line of CDVA in the WF optimized group, which was caused by a persistent irregular astigmatism, in absence of a flap complication. This postoperative outcome has been observed by Levinson et al in their study on complications leading to cornea specialist referral after LASIK.<xref ref-type="bibr" rid="b29-opth-5-1339">29</xref> One patient in our study experienced overcorrection in the WF guided group. Efforts to prevent overcorrection were attempted by comparing preoperative WaveScan refractions to manifest and cycloplegic refractions. The overcorrection did not impact this patient&#x02019;s postoperative UDVA, which was 20/20 with no subjective complaints. We attribute this UDVA in the setting of overcorrection to the patient&#x02019;s accommodation. This patient had a high degree of preoperative myopia with a high spherical equivalent, which has been correlated with LASIK overcorrection.<xref ref-type="bibr" rid="b30-opth-5-1339">30</xref></p><p>Limitations of the study include small sample size and short-term follow-up. We hope to continue to follow our study patients to better assess long-term outcomes. A possible limitation in comparing the VISX WF guided platform to the Allegretto WF optimized platform is that the VISX CustomVue WaveScan aberrometer is specifically designed for the VISX STAR S4 platform. One may argue that the aberrometer (WaveLight<sup>&#x000ae;</sup> Analyzer, Alcon, Inc, H&#x000fc;enberg, Switzerland) made for use with Allegretto may have shown different results. However, authors have used a single aberrometer platform to compare various wavefront lasers with consistent results.<xref ref-type="bibr" rid="b20-opth-5-1339">20</xref>,<xref ref-type="bibr" rid="b22-opth-5-1339">22</xref></p><p>Because the statistically significant differences between the platforms were small, we feel both WF optimized and WF guided platforms can provide safe and effective outcomes in LASIK. In our experience, the challenges associated with WF guided techniques included pupil size requirements, mismatch to MRX which was mostly due to over accommodation, and the timely process of uploading wavefront data. The Allegretto WaveLight Eye-Q laser functions at a higher frequency, therefore allowing faster operating times. Additionally, the Allegretto platform does not require iris registration, which can sometimes be difficult to obtain intraoperatively, and there is no issue with mismatch to MRX.</p><p>In conclusion, no significant differences were observed in regards to UDVA, CDVA, dry eye, or contrast sensitivity when comparing the WaveLight Allegretto Wave Eye-Q laser to the VISX CustomVue STAR S4 IR Excimer Laser with ActiveTrack iris registration. While the WF optimized platform showed superior outcomes for refractive measures of sphere and spherical equivalent, postoperative visual acuity was not statistically different between the study groups. Most WF optimized HOA values tended to increase, with a statistically significant increase in total HOA RMS. In contrast, there was a trend for WF guided HOA values to decrease, although not with statistical significance.</p></sec></body><back><ack><title>Acknowledgements</title><p>This investigation was supported by the University of Utah Study Design and Biostatistics Center, with funding in part from the Public Health Services research grant numbers UL1-RR025764 and C06-RR11234 from the National Center for Research Resources.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>Funding was provided from the Research to Prevent Blindness Foundation (New York, NY). The authors have no financial interests in any materials or products discussed in this paper or any other disclosures.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-opth-5-1339"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Barriuso</surname><given-names>E</given-names></name><name><surname>Lloves</surname><given-names>JM</given-names></name><name><surname>Marcos</surname><given-names>S</given-names></name><name><surname>Navarro</surname><given-names>R</given-names></name><name><surname>Llorente</surname><given-names>L</given-names></name><name><surname>Barbero</surname><given-names>S</given-names></name></person-group><article-title>Ocular aberrations before and after myopic corneal refractive surgery: LASIK-induced changes measured with laser ray tracing</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">11328757</pub-id></element-citation></ref><ref id="b2-opth-5-1339"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshika</surname><given-names>T</given-names></name><name><surname>Klyce</surname><given-names>SD</given-names></name><name><surname>Applegate</surname><given-names>RA</given-names></name><name><surname>Howland</surname><given-names>HC</given-names></name><name><surname>El Danasoury</surname><given-names>MA</given-names></name></person-group><article-title>Comparison of corneal wavefront aberrations after photorefractive keratectomy and laser in situ keratomileusis</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9932992</pub-id></element-citation></ref><ref id="b3-opth-5-1339"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zadok</surname><given-names>D</given-names></name><name><surname>Maskaleris</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>V</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Montes</surname><given-names>M</given-names></name><name><surname>Chayet</surname><given-names>A</given-names></name></person-group><article-title>Outcomes of retreatment after laser in situ keratomileusis</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>2391</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">10599677</pub-id></element-citation></ref><ref id="b4-opth-5-1339"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimbel</surname><given-names>HV</given-names></name><name><surname>van Westenbrugge</surname><given-names>JA</given-names></name><name><surname>Penno</surname><given-names>EE</given-names></name><name><surname>Ferensowicz</surname><given-names>M</given-names></name><name><surname>Feinerman</surname><given-names>GA</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name></person-group><article-title>Simultaneous bilateral laser in situ keratomileusis: safety and efficacy</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>1461</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">10442889</pub-id></element-citation></ref><ref id="b5-opth-5-1339"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farah</surname><given-names>SG</given-names></name><name><surname>Azar</surname><given-names>DT</given-names></name><name><surname>Gurdal</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Laser in situ keratomileusis: literature review of a developing technique</article-title><source>J Cataract Refract Surg</source><year>1998</year><volume>24</volume><fpage>989</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">9682123</pub-id></element-citation></ref><ref id="b6-opth-5-1339"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condon</surname><given-names>PI</given-names></name><name><surname>Mulhern</surname><given-names>M</given-names></name><name><surname>Fulcher</surname><given-names>T</given-names></name><name><surname>Foley-Nolan</surname><given-names>A</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>M</given-names></name></person-group><article-title>Laser intrastromal keratomileusis for high myopia and myopic astigmatism</article-title><source>Br J Ophthalmol</source><year>1997</year><volume>81</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">9135383</pub-id></element-citation></ref><ref id="b7-opth-5-1339"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knorz</surname><given-names>MC</given-names></name><name><surname>Liermann</surname><given-names>A</given-names></name><name><surname>Seiberth</surname><given-names>V</given-names></name><name><surname>Steiner</surname><given-names>H</given-names></name><name><surname>Wiesinger</surname><given-names>B</given-names></name></person-group><article-title>Laser in situ keratomileusis to correct myopia of &#x02212;6.00 to &#x02212;29.00 diopters</article-title><source>J Refract Surg</source><year>1996</year><volume>12</volume><fpage>575</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">8871858</pub-id></element-citation></ref><ref id="b8-opth-5-1339"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimbel</surname><given-names>HV</given-names></name><name><surname>Basti</surname><given-names>S</given-names></name><name><surname>Kaye</surname><given-names>GB</given-names></name><name><surname>Ferensowicz</surname><given-names>M</given-names></name></person-group><article-title>Experience during the learning curve of laser in situ keratomileusis</article-title><source>J Cataract Refract Surg</source><year>1996</year><volume>22</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">8784623</pub-id></element-citation></ref><ref id="b9-opth-5-1339"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guell</surname><given-names>JL</given-names></name><name><surname>Muller</surname><given-names>A</given-names></name></person-group><article-title>Laser in situ keratomileusis (LASIK) for myopia from &#x02212;7 to &#x02212;18 diopters</article-title><source>J Refract Surg</source><year>1996</year><volume>12</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">8653524</pub-id></element-citation></ref><ref id="b10-opth-5-1339"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkamthorn</surname><given-names>T</given-names></name><name><surname>Silao</surname><given-names>JN</given-names></name><name><surname>Torres</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Wavefront guided laser in situ keratomileusis in the treatment of high myopia by using the CustomVue wavefront platform</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>787</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">18650664</pub-id></element-citation></ref><ref id="b11-opth-5-1339"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalita</surname><given-names>MR</given-names></name><name><surname>Chavala</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Krueger</surname><given-names>RR</given-names></name></person-group><article-title>Wavefront analysis in post-LASIK eyes and its correlation with visual symptoms, refraction, and topography</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">15019317</pub-id></element-citation></ref><ref id="b12-opth-5-1339"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhren</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Kuhne</surname><given-names>A</given-names></name><name><surname>Kohnen</surname><given-names>T</given-names></name></person-group><article-title>Correlation of aberrometry, contrast sensitivity, and subjective symptoms with quality of vision after LASIK</article-title><source>J Refract Surg</source><year>2009</year><volume>25</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">19662912</pub-id></element-citation></ref><ref id="b13-opth-5-1339"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamane</surname><given-names>N</given-names></name><name><surname>Miyata</surname><given-names>K</given-names></name><name><surname>Samejima</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ocular higher-order aberrations and contrast sensitivity after conventional laser in situ keratomileusis</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>3986</fpage><lpage>3990</lpage><pub-id pub-id-type="pmid">15505046</pub-id></element-citation></ref><ref id="b14-opth-5-1339"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Miller</surname><given-names>DT</given-names></name></person-group><article-title>Supernormal vision and high-resolution retinal imaging through adaptive optics</article-title><source>J Opt Soc Am A Opt Image Sci Vis</source><year>1997</year><volume>14</volume><fpage>2884</fpage><lpage>2892</lpage><pub-id pub-id-type="pmid">9379246</pub-id></element-citation></ref><ref id="b15-opth-5-1339"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrochen</surname><given-names>M</given-names></name><name><surname>Kaemmerer</surname><given-names>M</given-names></name><name><surname>Seiler</surname><given-names>T</given-names></name></person-group><article-title>Wavefront guided laser in situ keratomileusis: early results in three eyes</article-title><source>J Refract Surg</source><year>2000</year><volume>16</volume><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">10766379</pub-id></element-citation></ref><ref id="b16-opth-5-1339"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohnen</surname><given-names>T</given-names></name><name><surname>Buhren</surname><given-names>J</given-names></name><name><surname>Kuhne</surname><given-names>C</given-names></name><name><surname>Mirshahi</surname><given-names>A</given-names></name></person-group><article-title>Wavefront guided LASIK with the Zyoptix 3.1 system for the correction of myopia and compound myopic astigmatism with 1-year follow-up: clinical outcome and change in higher order aberrations</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>2175</fpage><lpage>2185</lpage><pub-id pub-id-type="pmid">15582071</pub-id></element-citation></ref><ref id="b17-opth-5-1339"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name></person-group><article-title>Corneal higher-order aberrations after customized aspheric ablation and conventional ablation for myopic correction</article-title><source>Curr Eye Res</source><year>2007</year><volume>32</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">17514528</pub-id></element-citation></ref><ref id="b18-opth-5-1339"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randleman</surname><given-names>JB</given-names></name><name><surname>Perez-Straziota</surname><given-names>CE</given-names></name><name><surname>Hu</surname><given-names>MH</given-names></name><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Loft</surname><given-names>ES</given-names></name><name><surname>Stulting</surname><given-names>RD</given-names></name></person-group><article-title>Higher-order aberrations after wavefront optimized photorefractive keratectomy and laser in situ keratomileusis</article-title><source>J Cataract Refract Surg</source><year>2009</year><volume>35</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">19185240</pub-id></element-citation></ref><ref id="b19-opth-5-1339"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padmanabhan</surname><given-names>P</given-names></name><name><surname>Mrochen</surname><given-names>M</given-names></name><name><surname>Basuthkar</surname><given-names>S</given-names></name><name><surname>Viswanathan</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>R</given-names></name></person-group><article-title>Wavefront guided versus wavefront optimized laser in situ keratomileusis: contralateral comparative study</article-title><source>J Cataract Refract Surg</source><year>2008</year><volume>34</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">18299062</pub-id></element-citation></ref><ref id="b20-opth-5-1339"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Straziota</surname><given-names>CE</given-names></name><name><surname>Randleman</surname><given-names>JB</given-names></name><name><surname>Stulting</surname><given-names>RD</given-names></name></person-group><article-title>Visual acuity and higher-order aberrations with wavefront guided and wavefront optimized laser in situ keratomileusis</article-title><source>J Cataract Refract Surg</source><year>2010</year><volume>36</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">20202542</pub-id></element-citation></ref><ref id="b21-opth-5-1339"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miraftab</surname><given-names>M</given-names></name><name><surname>Seyedian</surname><given-names>MA</given-names></name><name><surname>Hashemi</surname><given-names>H</given-names></name></person-group><article-title>Wavefront guided vs wavefront optimized LASIK: a randomized clinical trial comparing contralateral eyes</article-title><source>J Refract Surg</source><year>2010</year><volume>27</volume><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">20839665</pub-id></element-citation></ref><ref id="b22-opth-5-1339"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brint</surname><given-names>SF</given-names></name></person-group><article-title>Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial</article-title><source>J Refract Surg</source><year>2005</year><volume>21</volume><fpage>S799</fpage><lpage>S803</lpage><pub-id pub-id-type="pmid">16329383</pub-id></element-citation></ref><ref id="b23-opth-5-1339"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stonecipher</surname><given-names>KG</given-names></name><name><surname>Kezirian</surname><given-names>GM</given-names></name></person-group><article-title>Wavefront optimized versus wavefront guided LASIK for myopic astigmatism with the ALLEGRETTO WAVE: three-month results of a prospective FDA trial</article-title><source>J Refract Surg</source><year>2008</year><volume>24</volume><fpage>S424</fpage><lpage>S430</lpage><pub-id pub-id-type="pmid">18500097</pub-id></element-citation></ref><ref id="b24-opth-5-1339"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>DB</given-names></name><name><surname>Shah</surname><given-names>V</given-names></name></person-group><article-title>Higher order aberrations comparison in fellow eyes following IntraLase LASIK with WaveLight Allegretto and CustomCornea LADARVision4000 systems</article-title><source>J Refract Surg</source><year>2006</year><volume>22</volume><fpage>S961</fpage><lpage>S964</lpage><pub-id pub-id-type="pmid">17124897</pub-id></element-citation></ref><ref id="b25-opth-5-1339"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Garamendi</surname><given-names>E</given-names></name><name><surname>Elliott</surname><given-names>DB</given-names></name></person-group><article-title>The Quality of Life Impact of Refractive Correction (QIRC) Questionnaire: development and validation</article-title><source>Optom Vis Sci</source><year>2004</year><volume>81</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">15557851</pub-id></element-citation></ref><ref id="b26-opth-5-1339"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshirfar</surname><given-names>M</given-names></name><name><surname>Espandar</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>JJ</given-names></name><name><surname>Tanner</surname><given-names>JR</given-names></name><name><surname>Holz</surname><given-names>HA</given-names></name></person-group><article-title>Prospective randomized trial of wavefront guided laser in situ keratomileusis with the CustomCornea and CustomVue laser systems</article-title><source>J Cataract Refract Surg</source><year>2007</year><volume>33</volume><fpage>1727</fpage><lpage>1733</lpage><pub-id pub-id-type="pmid">17889767</pub-id></element-citation></ref><ref id="b27-opth-5-1339"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Patient satisfaction and visual symptoms after wavefront guided and wavefront optimized LASIK with the WaveLight platform</article-title><source>J Refract Surg</source><year>2008</year><volume>24</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">18494340</pub-id></element-citation></ref><ref id="b28-opth-5-1339"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshirfar</surname><given-names>M</given-names></name><name><surname>Hatch</surname><given-names>BB</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Kurz</surname><given-names>CJ</given-names></name><name><surname>Eugarrios</surname><given-names>MF</given-names></name><name><surname>Mifflin</surname><given-names>MD</given-names></name></person-group><article-title>Prospective, contralateral comparison of 120-mum and 90-mum LASIK flaps using the IntraLase FS60 femtosecond laser</article-title><source>J Refract Surg</source><year>2010</year><volume>27</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">20672771</pub-id></element-citation></ref><ref id="b29-opth-5-1339"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levinson</surname><given-names>BA</given-names></name><name><surname>Rapuano</surname><given-names>CJ</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name><name><surname>Hammersmith</surname><given-names>KM</given-names></name><name><surname>Ayres</surname><given-names>BD</given-names></name><name><surname>Laibson</surname><given-names>PR</given-names></name></person-group><article-title>Referrals to the Wills Eye Institute Cornea Service after laser in situ keratomileusis: reasons for patient dissatisfaction</article-title><source>J Cataract Refract Surg</source><year>2008</year><volume>34</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">18165078</pub-id></element-citation></ref><ref id="b30-opth-5-1339"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biebesheimer</surname><given-names>JB</given-names></name><name><surname>Kang</surname><given-names>TS</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Hamilton</surname><given-names>DR</given-names></name></person-group><article-title>Development of an advanced nomogram for myopic astigmatic wavefront guided laser in situ keratomileusis (LASIK)</article-title><source>Ophthalmic Surg Lasers Imaging</source><year>2011</year><volume>42</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">21410091</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-opth-5-1339" position="float"><label>Figure 1</label><caption><p>Comparison of contrast sensitivity between allegretto and VISX laser platforms at 3, 6, 12, and 18 cycles per degree (CPD) preoperatively (n = 22) and at 3 months postoperatively (n = 22) using the Vectrovision CSV-1000E chart (<italic>P</italic> &#x02265; 0.066 for all measurements at any time).</p></caption><graphic xlink:href="opth-5-1339f1"/></fig><fig id="f2-opth-5-1339" position="float"><label>Figure 2</label><caption><p>Comparison of higher-order aberrations before surgery (n = 16) and 3 months postoperatively (n = 16) in the wavefront optimized platform. Total, coma, Z(3, 1), trefoil, Z(3, 3), and spherical aberration, Z(4, 0) were measured using the WaveScan at a mean diameter of 6 mm.</p><p><bold>Note:</bold> *Statistically significant (<italic>P</italic> = 0.012).</p><p><bold>Abbreviation:</bold> RMS HOA, root-mean-square higher order aberration.</p></caption><graphic xlink:href="opth-5-1339f2"/></fig><fig id="f3-opth-5-1339" position="float"><label>Figure 3</label><caption><p>Comparison of higher-order aberrations before surgery (n = 16) and 3 months postoperatively (n = 16) in the wavefront-guided platform. Total, coma, Z(3, 1), trefoil, Z(3,3), and spherical aberration, Z(4, 0) were measured using the WaveScan at a mean diameter of 6 mm (<italic>P</italic> &#x02265; 0.126).</p></caption><graphic xlink:href="opth-5-1339f3"/></fig><fig id="f4-opth-5-1339" position="float"><label>Figure 4</label><caption><p>Preoperative (n = 20) and 3 months postoperative (n = 20) comparison of mean Quality of Life Impact of Refractive Correction (QIRC) questionnaire scores (<italic>P</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="opth-5-1339f4"/></fig><table-wrap id="t1-opth-5-1339" position="float"><label>Table 1</label><caption><p>Preoperative group comparisons</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th colspan="2" align="left" valign="top" rowspan="1">Platform</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn2-opth-5-1339">*</xref></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Allegretto (n = 22)</th><th align="left" valign="top" rowspan="1" colspan="1">VISX (n = 22)</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">31.7 &#x000b1; 6.30</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male/female</td><td align="left" valign="top" rowspan="1" colspan="1">7/15</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean LogMAR CDVA</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.03 &#x000b1; 0.06 (&#x02212;0.125 to 0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.03 &#x000b1; 0.06 (&#x02212;0.125 to 0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDVA (20/X)</td><td align="left" valign="top" rowspan="1" colspan="1">18.6 &#x000b1; 2.28 (15 to 20)</td><td align="left" valign="top" rowspan="1" colspan="1">18.6 &#x000b1; 2.28 (15 to 20)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spherical equivalent (D)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.61 &#x000b1; 1.98 (&#x02212;7.25 to 1.50)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.86 &#x000b1; 1.81 (&#x02212;7.25 to &#x02212;0.375)</td><td align="left" valign="top" rowspan="1" colspan="1">0.137</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sphere (D)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.97 &#x000b1; 2.10 (&#x02212;7.75 to 1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.17 &#x000b1; 1.99 (&#x02212;7.5 to &#x02212;0.375)</td><td align="left" valign="top" rowspan="1" colspan="1">0.191</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cylinder</td><td align="left" valign="top" rowspan="1" colspan="1">0.70 &#x000b1; 0.97 (0 to 4.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.63 &#x000b1; 0.78 (0 to 2.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.461</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-opth-5-1339"><p><bold>Notes:</bold> Values represented as mean &#x000b1; standard deviation (range);</p></fn><fn id="tfn2-opth-5-1339"><label>*</label><p>paired Student&#x02019;s <italic>t</italic>-test.</p></fn><fn id="tfn3-opth-5-1339"><p><bold>Abbreviations:</bold> UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAR, logarithm of the minimum angle of resolution.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-opth-5-1339" position="float"><label>Table 2</label><caption><p>One month and three month visual acuity comparisons</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">Allegretto (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1">VISX (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn5-opth-5-1339">*</xref></th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Postoperative month 1</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UDVA (LogMAR)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.04 &#x000b1; 0.10 (&#x02212;0.125 to 0.176)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05 &#x000b1; 0.11 (&#x02212;0.125 to 0.301)</td><td align="left" valign="top" rowspan="1" colspan="1">0.515</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UDVA (20/x)</td><td align="center" valign="top" rowspan="1" colspan="1">19.3 &#x000b1; 5.19 (15 to 30)</td><td align="center" valign="top" rowspan="1" colspan="1">19.3 &#x000b1; 7.29 (15 to 40)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDVA (LogMAR)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05 &#x000b1; 0.08 (&#x02212;0.125 to 0.097)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.06 &#x000b1; 0.07 (&#x02212;0.301 to 0.097)</td><td align="left" valign="top" rowspan="1" colspan="1">0.745</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDVA (20/x)</td><td align="center" valign="top" rowspan="1" colspan="1">18.1 &#x000b1; 3.35 (15 to 25)</td><td align="center" valign="top" rowspan="1" colspan="1">17.6 &#x000b1; 3.01 (10 to 25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.329</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spherical equivalent (D)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 &#x000b1; 0.24 (&#x02212;0.05 to 0.625)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 &#x000b1; 0.51 (&#x02212;0.375 to 1.125)</td><td align="left" valign="top" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sphere (D)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.08 &#x000b1; 0.29 (&#x02212;0.75 to 0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.25 &#x000b1; 0.48 (&#x02212;0.5 to 1.75)</td><td align="left" valign="top" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cylinder (D)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 &#x000b1; 0.27 (0 to 0.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 &#x000b1; 0.17 (0 to 0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.234</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Postoperative month 3</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UDVA (LogMAR)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.07 &#x000b1; 0.09(&#x02212;0.125 to 0.301)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.07 &#x000b1; 0.09 (&#x02212;0.301 to 0.097)</td><td align="left" valign="top" rowspan="1" colspan="1">0.714</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UDVA (20/x)</td><td align="center" valign="top" rowspan="1" colspan="1">17.5 &#x000b1; 4.01 (15 to 30)</td><td align="center" valign="top" rowspan="1" colspan="1">17.3 &#x000b1; 3.69 (10 to 25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDVA (LogMAR)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.11 &#x000b1; 0.08 (&#x02212;0.301 to 0.097)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.10 &#x000b1; 0.09 (&#x02212;0.301 to 0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.909</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDVA (20/x)</td><td align="center" valign="top" rowspan="1" colspan="1">15.9 &#x000b1; 2.94 (10 to 25)</td><td align="center" valign="top" rowspan="1" colspan="1">16.1 &#x000b1; 3.06 (10 to 20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spherical equivalent (D)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 &#x000b1; 0.27 (&#x02212;0.375 to 0.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.30 &#x000b1; 0.43 (&#x02212;0.25 to 1.75)</td><td align="left" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sphere (D)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 0.31 (&#x02212;0.5 to 0.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.18 &#x000b1; 0.39 (&#x02212;0.25 to 1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cylinder (D)</td><td align="center" valign="top" rowspan="1" colspan="1">0.26 &#x000b1; 0.28 (0 to 0.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 &#x000b1; 0.28 (0 to 1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.623</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-opth-5-1339"><p><bold>Notes:</bold> Values represented as mean &#x000b1; standard deviation (range);</p></fn><fn id="tfn5-opth-5-1339"><label>*</label><p>paired Student&#x02019;s <italic>t</italic>-test.</p></fn><fn id="tfn6-opth-5-1339"><p><bold>Abbreviations:</bold> UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAR, logarithm of the minimum angle of resolution.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-opth-5-1339" position="float"><label>Table 3</label><caption><p>Efficacy, predictability, and safety comparison of allegretto and VISX laser platforms</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left" valign="bottom" rowspan="1">Postoperative month 1</th><th colspan="3" align="left" valign="bottom" rowspan="1">Postoperative month 3</th></tr><tr><th colspan="4" align="left" valign="bottom" rowspan="1"><hr/></th><th colspan="3" align="left" valign="bottom" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">Allegretto (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1">VISX (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn8-opth-5-1339">*</xref></th><th align="left" valign="bottom" rowspan="1" colspan="1">Allegretto (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1">VISX (n = 22)</th><th align="left" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn8-opth-5-1339">*</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Efficacy (UDVA)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.778</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20/15 or better</td><td align="left" valign="top" rowspan="1" colspan="1">10 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (55%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">14 (64%)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (59%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20/20 or better</td><td align="left" valign="top" rowspan="1" colspan="1">18 (82%)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (86%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">20 (91%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (91%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20/30 or better</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (91%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">21 (95%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20/40 or better</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20/50 or better</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Predictability</bold></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.035</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000b1;0.25 D of emmetropia</td><td align="left" valign="top" rowspan="1" colspan="1">10 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (27%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">17 (77%)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (68%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000b1;0.50 D of emmetropia</td><td align="left" valign="top" rowspan="1" colspan="1">21 (95%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (81%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">21 (95%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (82%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000b1;1.00 D of emmetropia</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (91%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Safety (CDVA)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Loss of 2 lines or more</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Loss of 1 line</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No loss of lines</td><td align="left" valign="top" rowspan="1" colspan="1">13 (62%)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (62%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">9 (41%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (55%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gain of 1 line</td><td align="left" valign="top" rowspan="1" colspan="1">5 (24%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (29%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">11 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (41%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gain of 2 lines or more</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn7-opth-5-1339"><p><bold>Notes:</bold> Values represented as number of eyes (percentege);</p></fn><fn id="tfn8-opth-5-1339"><label>*</label><p>paired Student&#x02019;s <italic>t</italic>-test.</p></fn><fn id="tfn9-opth-5-1339"><p><bold>Abbreviations:</bold> UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAR, logarirhm of the minimum angle of resolution.</p></fn></table-wrap-foot></table-wrap></floats-group></article>